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Abstract
Chronic conditions contribute to the majority of the mortality and morbidity burden in Europe. The extent to which infectious agents
are responsible for the chronic disease burden remains elusive. The complex nature of the natural history of chronic conditions calls
for an overview of ongoing research activities linking infectious agents with these conditions in order to guide research endeavours,
direct research funding, steer prevention efforts, and point health policy towards promising interventions. A selection of websites
hosted by institutions either ﬁnancing or conducting research within the European Union was screened for ongoing research activities
examining infectious aetiology of chronic conditions. The searches were conducted until September 2011, applying search strategies and
inclusion criteria predeﬁned in a study protocol. In total, 25 research activities met the inclusion criteria. Of those, ten activities were
focused to investigate infectious aetiology of cancer, four focused on type 2 diabetes mellitus, and 11 focused on a wide spectrum of other
chronic conditions. The identiﬁed research projects did not cover areas such as mental and behavioural disorders. Infectious agents analy-
sed included enteroviruses, Epstein-Barr virus, human rhinoviruses, P. gingivalis, human papillomaviruses, cytomegalovirus, Helicobacter spp.
and human parvovirus. Only three projects speciﬁcally addressed therapeutic interventions. Ultimately, linking infectious agents with
chronic conditions may translate into prevention efforts with vaccinations or treatment strategies with antimicrobial agents, and could,
thus, eventually reduce the heavy disease burden from chronic conditions. However, little translational research on therapeutic interven-
tions was found in our search and should be fostered, particularly for more established infectious-chronic disease associations.
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Introduction
Chronic conditions are responsible for the greatest burden
of ill health in Europe, accounting for 77% of the morbidity
and 86% of the mortality [1]. The aetiological origin of some
chronic conditions is not well understood [2,3]. Elucidating
the natural history of disease can help avert the initial (or
subsequent) infection, prevent the onset or progression of
disease, evade disability and avoid premature death. Infec-
tious agents have been suspected for long to be causally
linked to chronic conditions. Indeed, scientiﬁc advances over
the last 30 years have led to an increase in the number of
recognized infectious agents associated with the aetiology of
chronic conditions [4]. For example, peptic ulcer and gastric
cancer have been associated with Helicobacter pylori infection,
liver cirrhosis and cancer have been associated with hepatitis
B virus or hepatitis C virus infection, cervical cancer with
human papillomavirus infection, lyme arthritis and neurobor-
reliosis with Borrelia burgdorferi infection, and lymphoma with
Epstein-Barr virus (EBV) infection [5–8].
Infectious agents can cause a chronic condition through a
variety of pathways [3]; they can act directly or act in con-
cert with a co-factor (or trigger) in a complex series of
events, which ultimately progress to chronic disease [5,9].
There may be environmental, host and other microbial fac-
tors that contribute to the disease process. Pathogens might
be cleared rapidly after having interacted with their target,
such as in the case of Guillain-Barre´ syndrome, rheumatic
heart disease or Reiter’s syndrome [3]. Co-infections may
also play a role in the pathology. Often technical laboratory
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difﬁculties hamper the identiﬁcation of new and rare causa-
tive agents for which no effective diagnostic assays exist [5].
Thus, causally linking infectious agents to chronic conditions
has proven to be challenging. Establishing causal links
between infectious agents and chronic conditions requires
considerable research efforts and sustainable funding.
In order to help guide the future research enterprise in
this ﬁeld we conducted a review of ongoing research activi-
ties and networks addressing the infectious aetiology of
chronic conditions. Such a scoping exercise can uncover the
diversity of aetiological microbes and chronic conditions
under investigation, the range of pathogenic mechanisms and
the diagnostic methods under development. It can also iden-
tify research needs, obstacles and opportunities for the
detection, prevention and treatment of chronic conditions
caused by an infectious agent. The goal was to inform the
policy debate on future directions with regards to funding
and prioritization and to assure sustainability and interdisci-
plinary cooperation for translational research on treatment
and prevention. The scope was limited to the European
Union (EU) in order to complement expert assessments and
literature reviews that had been done elsewhere [2,3]. As
the EU is preparing a 7-year ﬁnancial and activity framework
(2014–2020), an insight into ongoing EU activities can con-
tribute to the policy-making process. Moreover, a snap shot
of participating organizations in the current research activi-
ties can contribute to the discussion on existing collaborative
schemes between European and overseas research institu-
tions. Tackling the infectious origin of chronic conditions is
scientiﬁcally and technically challenging, but preventing and
treating infections early can potentially reduce the human,
economic and societal costs of chronic conditions.
Methods
In order to indentify ongoing research activities within the
EU27, websites of WHO programmes and projects within EU
member states, EU institutions, international and national
research networks and ﬁnanciers were screened (Table 1).
International medical were also assessed profession associa-
tions (focusing on cancer, cardiovascular disease and diabetes),
national institutions for disease control (focusing on EU5:
France, Germany, Italy, Spain and the United Kingdom),
national health ministries (in EU5), and medical universities
and research institutions (EU top 10 within the top 50 ranking
at the Times higher education ranking 2010 for Life Sciences).
The searches were conducted in English, German and French
in May 2011 and were updated in September 2011.
The methodology applied for the searches is detailed in the
study protocol, which lists inclusion and exclusion criteria for
the search, the search strategy and keywords, and the actual
websites examined (Appendix S1). In brief, each website was
screened by one reviewer, any doubt regarding the inclusion
or exclusion of a research activity was discussed with a sec-
ond reviewer, and any discrepancies in the decision between
the reviewers was reconciled by a third reviewer. The search
strategies employed depended on whether the websites were
hosted by institutions ﬁnancing or conducting research
(Appendix S2): the search strategy for websites of institutions
ﬁnancing research were examined for information regarding
recipients of funds in the ﬁeld of infectious aetiology of
chronic conditions by navigating through pages and documents
listing funded projects in areas of interest (e.g. chronic condi-
tions and infectious diseases). If a funded research activity was
identiﬁed, further information on the project was searched
for on the receiving party’s website. If a search function was
available, funding-related keywords were used in combination
with disease-related, infection-related and association-related
keywords (for a list of the keywords used, see Appendix S1).
Similarly, websites of institutions conducting research were
screened for information regarding ongoing research activities
in the ﬁeld of infectious aetiology of chronic conditions by
navigating through the pages of research units conducting
research in the areas of interest. Again, if a search function
was available, disease-related, infection-related and associa-
TABLE 1. Data sources searched and number and type of research initiatives identiﬁed
Data sources Number of websites searched
Type of research initiatives identiﬁed
Individual project Collaborative project Research group
WHO and WHO agencies 3 0 0 1
EU institutions 8 1 8 0
International research councils, networks and ﬁnanciers 9 3 0 0
International medical professional associations 4 0 0 0
Local institutions for disease control (EU5)a 5 0 0 0
Health ministries (EU5) 5 0 0 0
National research councils, networks and ﬁnanciers (EU5) 9 2 0 0
Medical universities (EU top 10 ranked) 10 1 0 9
Total 53 7 8 10
(EU5)a: France, Germany, Italy, Spain and the United Kingdom
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tion-related keywords were used (Appendix S1). For institu-
tions that both ﬁnance and conduct research, both search
strategies described above were applied.
Results
Out of the 25 research activities identiﬁed, ten projects
were classiﬁed as belonging to research groups or units,
eight were collaborative research projects, and seven were
described as individual research projects (Table 1). The
details of the research activities are presented in Table 2, in
the following order: international/European-funded collabora-
tive projects, individual projects executed by a single institu-
tion or several institutions located with one country? A
detailed description of the research activities by organization
is available in Appendix S2.
The European Commission [10] was a major funding
source of research within this area, through the seventh
Framework Programme for Research and Technological
Development (FP7). Participation of countries from the EU
was not evenly distributed in the research networks and
consortiums; some countries (e.g. the UK, Sweden, Germany
and France) were over-represented.
In the consortiums funded by international/European orga-
nizations, non-EU countries (e.g. Israel, Switzerland and the
USA) participated as well.
The ongoing research activities identiﬁed in the current
study were concentrated to a few disease areas: neoplasms
(primarily cancer) and the endocrine system (primarily diabe-
tes (Table 2). Out of the 25 research activities identiﬁed, ten
focused on infectious aetiology of cancer, four on the infec-
tious aetiology of type 2 diabetes mellitus (T2DM), and the
remaining 11 focused on the infectious aetiology of a wide
spectrum of chronic conditions. However, none of the iden-
tied research activities focused on infectious aetiology of
blood conditions, endocrine conditions (other than diabetes)
mental conditions, or congenital malformations.
The research for a large number of projects focused on
mechanisms by which interactions between bacteria and
viruses enhance susceptibility and trigger chronic disorders
(e.g. investigating the mechanisms leading to the development
of virus-associated cancers). Only three (13%) mentioned
intervention or therapeutic strategies (MAARS, FLORINASH,
cytomegalovirus (CMV) pathogenesis in inﬂammation and
cancer).
Some research activities focused on multiple agents while
others did not specify the infectious agent. Infectious agents
affecting the digestive system were investigated in six
research projects (enterovirus, three projects; intestinal/gas-
trointestinal (micro) ﬂora, three projects) and the contribu-
tion of EBV to the aetiology of chronic conditions was
researched in three projects. A number of projects investi-
gated single infectious agents, for example, the microbiome
on the skin, human rhinoviruses, P. gingivalis, airborne or
commensal fungi, human papillomaviruses, cytomegalovirus,
cytolethal distending toxin-producing bacteria, Helicobacter
spp., commensal bacteria, and human parvovirus.
Thirty-two publications originating from the ongoing
research activities were identiﬁed, of which 16 were published
in 2011. Based on the information provided in the titles and
abstracts, six of these publications were likely to be experi-
mental in vitro or in vivo studies. The remaining ten publications
were, for example, epidemiological studies or reviews asses-
sing infectious aetiology of chronic conditions.
Discussion
Elucidating the pathogenesis of chronic conditions with an
infectious aetiology is essential to advance the ﬁeld. Under-
standing the natural history of disease and the underlying
molecular mechanisms is a foundation for the development of
novel treatment regimens. However, some of the associations
between infectious agents and chronic conditions are now well
established. For example, epidemiological studies have been
instrumental in conﬁrming the association between Campylo-
bacter infection and Guillain-Barre syndrome, H. pylori infec-
tion and peptic ulcers, EBV and malignant disease (e.g.
Burkitt’s lymphoma and Hodgkin’s disease), human herpes
virus-8 and Kaposi’s sarcoma, hepatitis B virus and hepatocel-
lular carcinoma, and human papilloma virus (HPV) and cervical
cancer [2]. It is desirable that discoveries in basic research are
translated rapidly and efﬁciently into meaningful health out-
comes, such as the antimicrobial treatment for H. pylori and
Campylobacter or the HPV vaccine currently available. Thus,
intervention studies examining prevention and/or treatment
strategies for these pathogens through vaccination or antimi-
crobial treatment should be advanced [7,11]. For these speciﬁc
pathogens, we identiﬁed the following research activities:
H. pylori infection and the mechanism of intestinal inﬂammation
and the mechanism of EBV-induced carcinogenesis. Transla-
tional research projects targeting these health outcomes with
randomized trials or cost-beneﬁt analyses for treatment and
prevention were under-represented in our scoping exercise.
Thus, even for those pathogens that have convincingly been
associated with a chronic condition, the research activities we
identiﬁed tended to focus on mechanistic and basic research
questions rather than translating these insights into public
health beneﬁts.
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A number of therapeutic interventions or prevention
strategies have already been developed for a few infectious
agents. They include H. pylori or HPV and neoplasms [12,13],
T. cruzi and chronic conditions of the circulatory system
[14], C. trachomatis and chronic conditions of the genitouri-
nary system [15], and H. pylori or T. whipplei and chronic
conditions of the digestive system [16]. Two of these infec-
tious agents are being investigated by research consortia
(Table 2).
From a public health perspective it would be desirable to
translate basic research into epidemiological studies, but in
this review only three research projects mention interven-
tions. Large pan-European population cohorts and health-
related registries can be an opportunity for collaborative
research activities regarding risk factors and the aetiology of
chronic conditions. However, these study populations should
also be used for longitudinal studies to assess the cost-effec-
tiveness of vaccination and antimicrobial treatment of infec-
tions that might result in chronic conditions later in life.
Some of the collaborative research projects, funded by
the European Union research program (FP7), investigated
the associations between infectious agents and chronic con-
ditions. The projects employed a range of novel approaches
(e.g. research design and intervention strategies) to obtain a
better understanding of the associations and to translate
research into practical clinical applications. The FP7 pro-
gramme will continue to provide funding for research until
2013. However, in contrast to previous years, the call for
2012 did not contain proposals within the ﬁeld of infectious
aetiology of chronic conditions [17].
The new WHO strategy for the prevention and control
of non-communicable diseases for 2012–2016 states that
there is a strong relationship between several non-communi-
cable diseases and infectious diseases [11]. However, none
of the identiﬁed actions for the WHO and member states
speciﬁcally aim to explore the aetiology of non-communica-
ble diseases.
It is important to underscore that for certain categories
of diseases the evidence of casual inference between infec-
tious agents and chronic conditions is weak and we observed
that current research does not cover this gap. Research pro-
jects on blood, endocrine and mental disorders, as well as
congenital malformations, were not identiﬁed in our search.
Limitations
Many of the reviewed websites for ongoing research initia-
tives were not regularly updated. Thus, recently initiated
research activities may not have been captured. HealthT
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research is typically funded by a number of public bodies,
charities and industry. Although we did not explicitly review
the charity sector (see annex A for the ones included) or
pharmaceutical research, they should, at least in part, be cap-
tured as part of the funding for universities in peer reviewed
publications which were not in the focus of this study as we
wanted to capture CURRENT research activities. Neverthe-
less, intervention research could inadvertently be under-rep-
resented in our sample. Completed research from previous
funding cycles (EU commission FP 4, 5 and 6) should be cap-
tured in the publications that were identiﬁed or on the uni-
versity websites. On a disaggregated member state level, the
search was limited to the EU5 countries, as these represent
the largest economies in Europe, and to the universities with
the highest ranked life science research within the EU.
Therefore, the aggregated data on participation of different
countries in research collaborative projects may be biased
and some countries may be over-represented. Despite these
limitations, this review marks the current trends in the
research activities within the ﬁeld of infectious aetiology of
chronic conditions in the EU.
Conclusions
This scoping exercise revealed that of the 25 research initia-
tives examined, eight were collaborative efforts with a num-
ber of scientiﬁc partners. It is precisely those multidisciplinary
initiatives that on their websites mention translational
research, therapeutic strategies and interventions (Table 2).
A successful strategy to tackle the infectious origin of chronic
conditions relies on an interdisciplinary approach that com-
bines basic research with therapeutic strategies and integrates
laboratory methods with epidemiological studies and surveil-
lance. Such a strategy will advance pathogen discovery, labo-
ratory detection methods, treatment and prevention.
Synergistic networks between research groups, combining
multidisciplinary research strategies, require longitudinal plan-
ning and programme management. For the EU, the added
value of enhanced research collaboration is to tackle limita-
tions imposed by scattered funding and fragmentation
between national programmes and to contribute to sustain-
able and long-lasting funding. Overall, the ongoing research
activities identiﬁed in this scoping exercise were impressive
and will contribute to increasing the knowledge around infec-
tious aetiology of chronic conditions. Nevertheless, there are
disease areas where further research is needed in order to
establish the role of infectious agents (e.g. endocrine, nutri-
tional and metabolic conditions). Research on uncertain asso-
ciations may lead to a better understanding of the
mechanisms leading to disease progression. However, based
on our assessment, it would be advisable to accelerate the
development of therapeutic options, encompassing vaccines
and other alternatives, speciﬁcally for the more well-estab-
lished infectious-chronic disease associations. This is particu-
larly important in the EU setting, with ageing populations and
increasing disease burden and healthcare costs.
In light of diminishing resources for public health due to
the economic downturn it is crucial to proceed strategically
with the most promising approach [18–20]. The most fruitful
tactic is based on crosscutting collaborations, integrating lab-
oratory sciences with epidemiological studies, and disease
surveillance (both chronic and infectious). Directing
resources to treatment and prevention of well-established
associations will increase the yield of investment in biomedi-
cal research and public health.
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